๐
Inrebic
fedratinib
Disturbi mieloproliferativi;Mielofibrosi primaria
โ
Autorizzato
โ
Nessun allarme attivo
Questo medicinale non presenta carenze in corso, lettere di sicurezza o richiami.
A cosa serve
Inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are Janus Associated Kinase (JAK) inhibitor naรฏve or have been treated with ruxolitinib.
โ ๏ธ Sicurezza del paziente
No
Pagina ufficiale EMA
https://www.ema.europa.eu/en/medicines/human/EPAR/inrebic